Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ONO-4578-02:ONO-4578 Phase 1 Study

ABSTRACT: Interventions: ONO-4578 given as combinations of ONO-4578, ONO-4538, XELOX and Bevacizumab Primary outcome(s): Safety, tolerability Study Design: non-randomized controlled trial, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2613172 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

ONO-7913-04: ONO-7913 Phase 1 Study

Project description:Interventions: Administration of ONO-7913 and ONO-4538 with FOLFOX and Bevacizumab or Cetuximab Primary outcome(s): Tolerability, safety Study Design: non-randomized controlled trial, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2613449 | ecrin-mdr-crc

Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Project description:The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.

| 2244525 | ecrin-mdr-crc

ONO-4538/CA2099X8 Phase 2/3 Study(ONO-4538-72/CA2099X8)

Project description:Intervention name : ONO-4538/BMS-936558 INN of the intervention : Nivolumab Dosage And administration of the intervention : Intravenous administration Control intervention name : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab INN of the control intervention : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab Dosage And administration of the control intervention : Intravenous administration Primary outcome(s): efficacy PFS Study Design: Randomized, open-label

| 2658327 | ecrin-mdr-crc

ONO-4538/CA2099X8 Phase 2/3 Study(ONO-4538-72/CA2099X8)

Project description:Interventions: investigational material(s) Generic name etc : ONO-4538/BMS-936558 INN of investigational material : Nivolumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous administration control material(s) Generic name etc : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab INN of investigational material : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous administration Primary outcome(s): efficacy PFS Study Design: Randomized, open-label

| 102159 | ecrin-mdr-crc

Synthetic prostacyclin ONO-1301 Enhance Survival of Human Pluripotent Stem Cell-Derived Cardiomyocytes Tissue Transplantation in a Rat Myocardial Infarction Model

Project description:To investigate whether ONO-1301 activates angiogenesis-related signaling pathways in 253G1 derived cardiomyocytes

2023-03-26 | GSE205622 | GEO

iPac-02 trial

Project description:Interventions: mFOLFOX6 + bevacizumab + IP PTX therapy:1 course for 14 days intraperitoneal paclitaxel on days 1 and 8, Intravenous infusion of bevasizumab (Bmab), levofolinate (l-LV), oxaliplatin (L-OHP), followed by bolus of fluorouracil (5-FU) on day 1. CAPOX + bevacizumab + IP PTX therapy:1 course for 21days intraperitoneal paclitaxel on days 1, 8 and 15, Intravenous infusion of bevasizumab (Bmab) and oxaliplatin (L-OHP) on day 1, oral Capecitabine on days 1-14. Primary outcome(s): Response rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2740711 | ecrin-mdr-crc

Gene expression profiling of biopsy and resection samples from the DEBIOC phase 1 trial of oxaliplatin and capecitabine +/- AZD8931 in oesophageal cancer

Project description:The Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC) trial reported an acceptable safety profile for neoadjuvant Oxaliplatin and Capecitabine (Xelox) +/- AZD8931 in oesophageal adenocarcinoma (OAC) but limited efficacy. We evaluated the impact of neoadjuvant Xelox +/-AZD8931 on biological pathways using a unique software-driven solution. Transcriptomic profiles from 25 pre-treatment FFPE OAC biopsies and 17 matched resection specimens, treated with Xelox+AZD8931 (n=16) and Xelox alone (n=9), were analysed using the Almac claraT total mRNA report. Tumour Infiltrating Lymphocytes (TILs) were assessed digitally using QuPath software. Hierarchical clustering identified three molecular subgroups classified by activation of innate immune signalling. The Immune High subgroup was associated with HER2 positivity, increased pathological response and a marked reduction in immune signalling and TILs following neoadjuvant therapy. The Immune Low cluster was pre-dominantly HER2/EGFR negative and EGFR positivity was associated with the Immune Mixed subgroup. Neoadjuvant therapy induced angiogenesis and EMT signalling and a reduction in DNA repair signatures with AZD8931 also promoting an immunosuppressive microenvironment. OAC may be subdivided into three immune-related subgroups which undergo modulation in response to neoadjuvant therapy with marked suppression of the immune microenvironment in HER2 positive/Immune High tumours.

2024-09-01 | E-MTAB-13741 | biostudies-arrayexpress

Bradyrhizobium sp. USDA 4538 isolate:USDA 4538

Project description:Bradyrhizobium sp. USDA 4538 genome sequencing

| PRJNA708369 | ENA

Genomic effects of an EP4-receptor agonist in airway epithelia

Project description:It has been proposed that inhaled EP4-receptor agonists could represent an alternative class of bronchodilators for the treatment of asthma that are as effective as β2-adrenoceptor agonists. However, the genomic impact of such drugs is often overlooked despite being potentially deleterious to respiratory health. Herein, we used mRNA-seq to compare the genomic impact of ONO-AE1-329 (an EP4-receptor agonist) and vilanterol (a β2-adrenoceptor agonist) in BEAS-2B human airway epithelial cells. We also determined if an increase in cAMP mediated by different GPCRs promoted distinct transcriptional signatures by expanding this enquiry to include the adenosine A2B- and I-prostanoid receptor agonists, Bay-60-6583 and taprostene, respectively. Maximally-effective concentrations of ONO-AE1-329 and vilanterol significantly regulated (q ≤ 0.05; ≥1.5-/≤0.67-fold) 232 and 320 genes, respectively of which 217 were shared. Spearman analysis showed these gene expression changes to be highly rank order correlated indicating that the functional overlap between the two interventions should be considerable. Unexpectedly, the genomic effects of ONO-AE1-329, vilanterol, Bay 60-6583 and taprostene were also highly rank order correlated. This finding raises the prospect that cAMP generated by any GPCR would initiate the same transcriptional program. Nevertheless, relative to vilanterol, ONO-AE1-329 typically behaved as a partial agonist with a potency and intrinsic activity that varied across transcripts. Collectively, this investigation demonstrated that each ONO-AE1-329-regulated gene differs in sensitivity to cAMP and is defined by a unique receptor occupancy-response relationship. Moreover, if this relatively modest genomic response in BEAS-2B cells is reproduced in vivo, then inhaled EP4-receptor agonists could represent a safer class of bronchodilators.

2025-05-04 | GSE267218 | GEO

Project description:Synbiotic tolerability study

| PRJNA811803 | ENA